U.S. markets open in 8 hours 41 minutes
  • S&P Futures

    3,637.25
    +4.50 (+0.12%)
     
  • Dow Futures

    30,025.00
    +27.00 (+0.09%)
     
  • Nasdaq Futures

    12,118.50
    +42.50 (+0.35%)
     
  • Russell 2000 Futures

    1,853.10
    +1.60 (+0.09%)
     
  • Crude Oil

    45.17
    +0.26 (+0.58%)
     
  • Gold

    1,802.20
    -2.40 (-0.13%)
     
  • Silver

    23.18
    -0.12 (-0.52%)
     
  • EUR/USD

    1.1906
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    0.8820
    -0.8820 (-100.00%)
     
  • Vix

    21.64
    -22.66 (-100.00%)
     
  • GBP/USD

    1.3347
    -0.0012 (-0.09%)
     
  • USD/JPY

    104.4700
    -0.0100 (-0.01%)
     
  • BTC-USD

    18,803.94
    -264.55 (-1.39%)
     
  • CMC Crypto 200

    372.70
    +2.95 (+0.80%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,323.01
    +157.42 (+0.60%)
     

Recap: Inovio Pharmaceuticals Q3 Earnings

Benzinga Insights
·1 min read

Shares of Inovio Pharmaceuticals (NASDAQ:INO) increased 2.94% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 4.00% year over year to ($0.26), which missed the estimate of ($0.19).

Revenue of $236,178,000 up by 27145.14% year over year, which beat the estimate of $3,050,000.

Outlook

Inovio Pharmaceuticals hasn't issued any earnings guidance for the time being.

Inovio Pharmaceuticals hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 09, 2020

View more earnings on INO

Time: 04:30 PM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2021/38428

Price Action

52-week high: $33.79

Company's 52-week low was at $2.19

Price action over last quarter: down 40.29%

Company Overview

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.